Gene therapy for rare genetic syndrome moves to Long-Term safety check

NCT ID NCT07690527

First seen Jul 08, 2026 · Last updated Jul 14, 2026 · Updated 4 times

Summary

This study follows children with Phelan-McDermid syndrome (a rare genetic disorder causing developmental delays) who received a single dose of RB001 gene therapy injected into the brain. Researchers will monitor them for up to 5 years to see if the treatment is safe and whether it improves symptoms. The goal is to understand if this one-time gene therapy can help manage the condition long-term.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RB001 (gene therapy)
What this could lead to
If successful, this gene therapy could reduce symptoms of Phelan-McDermid syndrome, potentially improving quality of life for affected children.
What could go wrong
This is an early, small study (8 participants) testing safety first. Gene therapies can have side effects, and it is unknown if the benefits will last or outweigh risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHELAN-MCDERMID SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, China, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.